When was Rallybio founded?

Rallybio was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Rallybio located?

Rallybio is headquartered in Farmington, United States.

Who is the current CEO of Rallybio?

Martin Mackay of Rallybio. They have also founded 1 company.

How many employees does Rallybio have?

As of Sep 30, 2026, the latest employee count at Rallybio is 22.

Is Rallybio a funded company?

Rallybio is a funded company, having raised a total of $182M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 20, 2018.

When was the latest funding round of Rallybio?

Rallybio's latest funding was a $***** Post IPO round on Apr 10, 2024, with participation from 0 investor.

What is the annual revenue of Rallybio?

Annual revenue of Rallybio is less than $1M as on Dec 31, 2025

Where does Rallybio rank among its competitors?

Rallybio ranks 21st amongst 284 active competitors, of which 76 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Rallybio?

Rallybio's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Rallybio - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of antibodies & protein therapies for rare disorders. The company is building a broad and sustainable pipeline of product candidates to treat rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, ophthalmology, and metabolic disorders.

Website: rallybio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Farmington, United States

Stage

Public

Total Funding

$182M in 3 rounds

Latest Funding Round

Post IPO, Apr 10, 2024, $*****

Investors

Canaan & 12 more

Ranked

21^st among 284 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2025

Employee Count

22 as on Sep 30, 2026

Similar Companies

BridgeBio & 318 more

Exit Details

Public

View Rallybio's full profile

Rallybio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
RALLYBIO CORP CIN: 1739410 , United States, Active	May 06, 2018	$0 - $1M (As on Dec 31, 2025)	43 (As on Dec 31, 2023)	-

Rallybio got listed on Jul 29, 2021.

Click here to take a look at Rallybio's IPO in detail

Rallybio has raised a total funding of $182M over 3 rounds. Its first funding round was on Apr 20, 2018. Rallybio has 13 institutional investors.

Here is the list of recent funding rounds of Rallybio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 10, 2024	1214442	Post IPO	7445269	8606441	9463982	2742488
Mar 27, 2020	8418937	Series B	1609395	5049927	7162616	Mitsui Global Investment & 11 more
Apr 20, 2018	4578848	Series A	7421636	7769288	5AM Ventures & 2 more	Connecticut Innovations

Access funding benchmarks and valuations. Sign up today!

View details of Rallybio's funding rounds and investors

The founders of Rallybio are Martin Mackay and Stephen Uden. Martin Mackay is the CEO of Rallybio.

Here are the details of Rallybio's key team members:

Martin Mackay: Co-Founder & CEO of Rallybio.
Stephen Uden: Co-Founder of Rallybio.
Contact Info: 1 email address

View details of Rallybio's Founder profiles and Board Members

Rallybio's employee count trend

Rallybio has 22 employees as of Sep 26. Here is Rallybio's employee count trend over the years:

Uncover Rallybio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rallybio include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Rallybio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
6th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
7th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
8th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
9th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
10th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	67/100
21st	Rallybio 2018, Farmington (United States), Public	Developer of antibodies & protein therapies for rare disorders	$182M	New Leaf Venture Partners, Canaan & 11 others	64/100